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women. Evaluation of AMH’s predictive value in the natu-
rally aging population is important for counseling women 
about reproductive planning as well as for treatment plan-
ning for women experiencing hormone-sensitive gyneco-
logical conditions such as endometriosis and fibroids.
Conclusions  AMH can be considered as an indicator of 
fertility in late reproductive age women and pregnancy 
outcome in assisted reproductive technology cycles. AMH 
can strongly predict poor response in the controlled ovarian 
stimulation.
Keywords Fertility · Late reproductive age · Anti-
Müllerianhormone · Pregnancy
Introduction
Fertility can be defined as natural capability for having off-
spring and measured using fertility rate, i.e., the number of 
live births per 1000 women. In demographic or socioeco-
nomic context, fertility is measured using total fertility rate 
index, which is a the total number of children per women 
during her whole life [1]. It is well known that women’s fer-
tility is strictly dependent on individual’s age and that fertil-
ity peak occurs in the early 20s and it starts to decline in 
the third and fourth decades of life (falling sharply after age 
35) [2]. Menopause is understood as a natural cessation of 
women’s reproductive ability. It typically occurs in women 
in late 40s and early 50s [3]. Therefore, conceiving a baby 
by women between older than 35 years old can be regarded 
as fertility in late reproductive age. It has been estimated 
that at age 35 and 40, 66 and 44 % women, respectively, 
will have a conception ending in live birth within 1 year [4].
Smith and Buyalos [5] prepared the statistical analy-
sis which presented the age-dependent decrease in female 
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fertility. This decline in fertility rate is becoming clearly 
visible at the female age 38 years.
According to these data, the median age at last birth is 
40–41 years old across a range of natural fertility popula-
tions. Therefore, the start of a “natural infertility” period 
can be estimated to start about 8 years before menopause.
In this review, we will briefly review available data con-
cerning the causes of decrease of fertility in late reproduc-
tive age and possible diagnostic tools for its assessment.
Causes of decreased fertility
There are a lot of factors responsible for decrease of fertil-
ity in women of late reproductive age. These factors can 
be classified as oocyte-dependent and oocyte-independent 
[5]. The first group refers to the decreasing number and 
quality of oocytes with advancing age, and the second is 
related to reproductive organs (uterus, oviducts) and gen-
eral health.
Oocyte‑dependent causes
The loss of oocytes is a continuous process that begins just 
after the establishment of the oocyte pool during fetal life. 
At approximately 20 weeks’ gestation, the ovaries in the 
female fetus contain 6–7 million oocytes, but this number 
falls rapidly. In total, 1–2 million oocytes remain at birth, 
and only 300,000–500,000 are present at age of 13 at the 
onset of puberty [6]. In perimenopausal women, we can 
find only few hundred (750–1000) of oocytes [7]. If we 
realize that during reproductive period only 500 oocytes 
can ovulate, it is obvious that vast of those are lost through 
apoptosis.
Recent studies presented the model to evaluate the 
decrease in ovarian nongrowing follicle reduction in rela-
tion to female aging [8] showing that the rate at which 
ovarian nongrowing follicles are lost changes smoothly 
rather than suddenly.
With the loss of ovarian follicular pool, women experi-
ence cycle shortening, menstrual irregularity, infertility, 
sterility and finally menopause. Changes in menstrual regu-
larity are observed approximately 6 years before the begin-
ning of menopause [7, 9].
Child-bearing usually ends 8–0 years before menopause, 
and this time period is consistent regardless of the age of 
menopause [9].
Selection of a dominant follicle which occurs earlier 
than normally and is caused by the shortening of the first 
phase of menstrual cycle in older women [10]. Broekmans 
et al. [11] reviewed the contemporary knowledge of the 
ovarian aging in relation to fertility and menopause.
Age affects not only the size of the oocyte pool but also 
the quality of germ cells. Farr et al. [12] studied the num-
ber of live births in different age groups after transfers of 
embryos from eggs from donors in comparison with live 
births after ART cycles using woman’s own eggs. The 
results showed that the pregnancy rate depends mostly on 
the age of oocyte donor and the live births rate in ART 
declines with female age. Even in women of advanced age 
(up to 60 years old), if the oocyte donor were young (20s to 
early 30s) the number of life births remains relatively high) 
[9].
Other proof for decreasing quality of oocytes with age is 
rate of oocyte aneuploidy. The rate is low for women by up 
to age 35 (53 % in embryos after 3 days from fertilization), 
but increases to 74 % at the age of 41–42, and to 93 % after 
the age of 42 [13].
Oocyte quality declines with age and seems to be, at 
least partially, dependent on meiotic errors. It has been 
shown that meiotic spindles are more diffuse in older 
women [14, 15]. It has been proposed that one of the 
important mechanisms influencing chromatin division is a 
function of oocyte mitochondria. This hypothesis is based 
on findings of abnormal spindles and chromosomal scat-
tering in oocytes deficient in the pyruvate-metabolizing 
enzyme Pdha1 [16].
Also the oocyte selection process seems to become more 
aberrant with age. Available data from IVF cycles show 
that in the selection is less discriminating, which allows 
maturation of follicles, which in younger women would 
have undergone atresia [17].
Oocyte‑independent causes
In addition to the changes discussed above related to oocyte 
quality, the ability to achieve and maintain a pregnancy 
is also dependent on the uterus. Decidual and placental 
development and embryo implantation are strictly uterus 
dependent, but epidemiological data show weak association 
between maternal age and stillbirth rate [18]. This correla-
tion remains even after correction for potential confound-
ers, including fetal chromosomal abnormalities, multiple 
pregnancy, obesity, pre-eclampsia, insulin-dependent dia-
betes and multiple pregnancy [19]. Animal studies allowed 
identification of some of the factors contributing to this 
correlation. In mice, older ones showed an impairment of 
artificially induced decidual response in comparison with 
the young [20]. There was an observed tendency for com-
pensatory placental hypertrophy in older individuals [21]. 
Therefore, decidualization and placentation processes may 
be impaired in women of advanced age.
Recently some data have been published about possi-
ble role of cumulus cells function in the process of ovarian 
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aging [22]. Oocyte function is dependent on its microen-
vironment, and the bidirectional communication between 
the cumulus cells and the oocyte plays a crucial role. It 
has been noted that aging is connected with an increase 
in expression of genes related to angiogenesis in cumulus 
cells. One of the proposed mechanisms affecting chromo-
some segregation is hypoxia [25].
Other factors related with advancing women’s age such 
as uterine pathology, fibroids, endometriosis and endome-
trial polypus, dysfunctional response of endometrium to 
hormonal stimulation and finally general health (cardiovas-
cular diseases, metabolic diseases, oncological diseases) 
can also be considered [23].
Short summary of available data concerning role 
of AMH in determination of ovarian reserve 
and physiological rationale
Anti-Müllerian hormone (AMH) is a dimeric glycoprotein 
of the transforming growth factor-β (TGF-β) superfamily 
involved in cell growth and differentiation [24]. It is pro-
duced directly by the ovarian granulosa cells of secondary, 
preantral, and early antral follicles up to 6 mm in diameter, 
and its secretion ceases as follicles grow into dominance 
[25].
AMH production was first demonstrated almost 35 years 
ago by Hutson et al. [26].
This hormone appears in the 36th week of gestation and 
decreases continuously through puberty. It becomes unde-
tectable when menopause occurs [27]. There are only slight 
changes in serum AMH level during the menstrual cycle 
and AMH can be measured at any day of the menstrual 
cycle. The main physiological role of AMH in the ovary 
seems to be limited to the inhibition of early stages of fol-
licular development and prevention of the recruitment of a 
nondominant follicle [28].
Serum AMH levels have been shown to correlate with 
ovarian reserve (follicular pool) [29]. It has been used as 
an ovarian reserve marker since 2002 [30]. Ovarian reserve 
can be defined as the number and quality of follicles in the 
ovary at any given time. Evaluation of ovarian reserve is 
recommended for patients who are at risk of decreased or 
diminished ovarian reserve (DOR). Although the level of 
AMH is a good predictor of oocyte quantity, it may not 
provide information about egg quality. Thus, young women 
with low AMH levels may have a reduced number of 
oocytes but normal, age-appropriate oocyte quality [31].
In 2003, Fanchin et al. demonstrated that antral follicle 
count (AFC) was closely related to serum AMH level on 
the third day of cycle in infertile women. This correlation 
was shown to be stronger than with other hormonal mark-
ers such as inhibin B, E2, and FSH [32].
Many studies have shown that AMH is currently the best 
available measure of ovarian reserve applicable in a vari-
ety of clinical situations, such as infertility treatment (espe-
cially IVF), forecasting of reproductive lifespan, ovarian 
dysfunction (especially polycystic ovary syndrome), and 
gonadotoxic cancer treatment or ovarian surgery. Moreo-
ver, AMH may help to individualize ovarian stimulation 
protocols, thereby improving the efficiency and safety of 
IVF [33].
Evolution of AMH measurements methods
The first AMH assay was described by Hudson et al. [34] 
in 1990. The first commercially available assays (so-called 
first-generation assays) were introduced by Diagnostic Sys-
tems Laboratories (DSL) and Immunotech Ltd (IOT). Each 
new assay used different standards and antibodies. The 
majority of studies showed that the results obtained with 
the IOT assay had been higher in comparison with the DSL 
kit. However, there were also some data that had shown 
their equivalence [35–37].
The ELISA Gen II Assay (Gen II) was introduced by 
Beckman Coulter in November 2010 aiming to combine 
and replace the two first-generation methods. In the pre-
liminary studies, Kumar et al. [38] found that the results 
obtained with this assay had been correlated and higher 
than those given by DSL. The similar results were shown 
by Wallace et al. and Nelson and La Marca [39, 40] who 
found the 40 % higher concentrations obtained by Gen II 
assay. Surprisingly, the next investigation presented dif-
ferent results in which AMH results obtained with Gen II 
were found to be 20–40 % lower than those measured using 
the DSL assay [41].
These discrepancies led to confusion among scientists 
and clinicians. Many factors, e.g., sample storage condi-
tions (−20 vs. −80 C), storage time prior to assessment of 
sample (fresh vs. storage of 7 days), and other preanalytical 
and analytical conditions could lead to different results and 
finally lack of reliability of methods [41, 42].
The retrospective analysis of 8323 blood samples 
that compared IOT assay with Gen II found that the cor-
relations of clinical results with the patient AMH level 
showed large differences depending on the AMH assay 
used. These varying values of AMH depending on the 
particular assay used could result in erroneous clini-
cal decisions with regard to stimulation protocols in 
IVF [42]. Additionally, the letter published in Fertil-
ity and Sterility noted that patients with a high risk of 
ovarian hyperstimulation syndrome (OHSS) should have 
their AMH tested paying careful attention to the test 
used in order to avoid applying an unsuitable stimula-
tion protocol [43]. The request for explanation of such 
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discrepancies in results directed to Beckman Coulter 
remained unanswered.
However, the observed discrepancies resulted in the 
withdrawal of the Gen II assay from the market in July 
2013 (Beckman Coulter UK Urgent Field Safety Notice 
20434-3). The next step in development of AMH assay 
was the introduction of a new modified the Gen II assay 
(Gen IIm) in August 2013. The novelty of that method was 
based on preliminary premixing of the calibrator, control, 
or serum and assay buffer to the ELISA plate instead of a 
sequential step as in the previous kit [44, 45].
In 2014, Ansh Labs introduced two new AMH ELI-
SAs. They were marketed as an ultra-sensitive Ansh Labs 
ELISA (Ansh-US) for standard use and a picoAMH (Ansh-
pico) assay for use in samples with lower AMH. The Ansh-
US assay performance characteristics are similar to the Gen 
IIm. Additionally, it was demonstrated that Ansh-pico has 
enhanced sensitivity in comparison with previous methods 
and could be used when low AMH levels were expected. 
All above described assays were manual ones [46, 47].
The recent years have brought forth the introduction of 
totally automatic methods: Elecsys® AMH assay by Roche 
Diagnostics and Access AMH developed by Beckman 
Coulter. These automatic methods avoid the influence of 
handling methods on AMH results. Additionally, the results 
are obtained faster; they have low inter-laboratory vari-
ability and finally have better reproducibility than manual 
assays [48–51].
AMH as an indicator of fertility in late 
reproductive age women, spontaneous pregnancy 
rate, and pregnancy outcome
As mentioned above, AMH levels have been shown to 
be age dependent [52]. The decrease in AMH levels that 
occurs with increased age may be noted before changes in 
other age-related variables, suggesting serum AMH levels 
may be the best marker of ovarian aging [53].
However, it should be noted that AMH natural values 
show large inter-individual variability by age, indicating a 
wide range of ovarian reserve among the healthy popula-
tion [54].
Cui et al. [55] studied median AMH levels in Chinese 
women across different age groups. Their results were as 
follows: 2.35 ng/mL for ages 20–31 years, 1.58 ng/mL 
for ages 32–34 years, 1.30 ng/mL for ages 35–37 years, 
0.96 ng/mL for ages 38–40 years, 1.05 ng/mL for ages 
41–43 years, and 0.67 ng/mL for ages >43. This study 
shows the significance of serum AMH levels decrease with 
increasing age.
AMH has emerged as marker of ovarian reserve and 
possible surrogate measure of reproductive aging. Freeman 
et al. [56] found that AMH was a stronger predictor of 
median time to menopause than FSH and inhibin b in late 
reproductive age women. Similar results were published by 
Depmann et al. [57].
From this point of view, evaluation of AMH’s predic-
tive value in the naturally aging population is important for 
counseling women about reproductive planning as well as 
for treatment planning for women experiencing hormone-
sensitive gynecological conditions such as endometriosis 
and fibroids.
There are a very limited number of studies analyz-
ing fecundability in women of advanced reproductive age 
who want to conceive naturally. It results from the fact that 
AMH has been used primarily to assess fertility of women 
undergoing assisted reproduction procedures. Steiner et al. 
[58] studied women in their late reproductive life (30–
42 years). In this study, reduced fecundability was found 
in women with very low AMH levels (<0.7 ng/ml). Con-
trary low AMH in healthy women in their mid-20s did not 
predict reduced fecundability [59]. Additional studies are 
required to estimate ability of AMH to predict the chance 
of spontaneous pregnancy in young and particularly in late 
reproductive age women.
Freeman et al. [60] analyzed the hypothesis that AMH 
levels are lower in obese women of late reproductive age in 
comparison with nonobese women in the same age group, 
and found it to be true. These findings offer further evi-
dence of the complex relationships between obesity and 
reproductive hormone levels in women.
Ovarian reserve testing should be performed for women 
older than 35 years who have not conceived after 6 months 
of attempting pregnancy and women at higher risk of 
diminished ovarian reserve. At present, it is ACOG Com-
mittee’s opinion that ovarian reserve testing results cannot 
be extrapolated to predict the likelihood of spontaneous 
conception (ACOG) [61].
AMH as an indicator of fertility in late 
reproductive age women and pregnancy outcome 
in ART cycles
It is a well-known fact that female fertility is diminished 
with increasing age. According to some data, the atresia 
of follicle pool is accelerated in women over 37–38 years. 
When analyzing IVF results published by Human Fertiliza-
tion and Embryology Authority (HFEA), the live birth rate 
for the age range 40–42 was 12.7, 5.1 % for ages 43–44, 
and 1.5 % for women aged 45 and older [62]. It is well 
established that the success of IVF procedures depends 
on many factors among which the most important and 
independent ones are: age and serum AMH concentration 
[63–66]. AMH can strongly predict poor response in the 
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controlled ovarian stimulation. Despite presented results, 
the data still showed that women over 40 years with very 
low AMH concentrations had a chance of pregnancy [67].
There are some studies showing the possibility of preg-
nancy and live birth in women with low and extremely low 
AMH and older than 40 years.
Lee et al. [68] found no clinical pregnancies in women 
over 40 years who had AMH <0.48 ng/mL. In the study 
presented by Nelson et al. [69], the small group of 26 
women with extremely low AMH concentrations ≤0,15 ng/
ml achieved no pregnancy during antagonist or modified 
natural IVF. The age of women was up to 44 years.
In contrast, Weghofer et al. [70] presented a retrospec-
tive study showing 1.7 % deliveries per cycle for patients 
42 years of age. The cutoff value for AMH was set out in 
this study on ≤0.4 ng/ml. The pregnancy chances were also 
presented by Łukaszuk et al. [71] who showed that among 
women with low AMH (≤0.4 ng/ml) who had undergone 
long agonist treatment had 5.6 % clinical pregnancy and 
2.8 % live birth per patient in group of women >39 years.
Among 48 cycles of women aged >42 with AMH lev-
els of ≤0.2 ng/ml, no pregnancies were observed in Kedem 
study. In the same study, 3 ongoing pregnancies out of 192 
cycles (1.6 %) were recorded for women with AMH lev-
els in the range of 0.2–1.0 ng/ml [72]. Bhide et al. [73] 
presented data showing reasonable pregnancy chances in 
women over 40 years at the rate of 5/54 (9.3 %) when AMH 
was below 10.28 pmol/l. Additionally, no cutoff AMH 
was established below which pregnancy was excluded. 
Reicheman et al. [74] found 3.9 % clinical pregnancy rate 
in women with AMH <0.17 ng/ml and >42 years. Seifer 
et al. [75] conducted the largest study in this area analyz-
ing AMH concentrations in over 5000 cycles from the 
Society for Assisted Reproductive Technology Clinic Out-
come Reporting System Database for 2012–2013. Accord-
ing to their data, the cycles of women with the AMH con-
centration lower than 0.16 ng/mL had a greatest risk of 
cancelation.
The different results in all above studies could be par-
tially explained by different assays applied in different 
years [75]. In addition, even the similar kits achieved higher 
or lower values during the same time. Our unpublished data 
also suggested that AMH could vary even during the same 
menstrual cycle. Thus, the simple comparison of the results 
from the various studies may be seriously flawed. It seems 
that nowadays only the new totally automated assays such 
as Roche Elecsys could provide data that could give com-
parable results.
Based on available data, the pregnancy chances for 
women of advanced reproductive age with low AMH and 
especially for those over 42 years old are very low but still 
the available methods fail to dependably predict who will 
become pregnant.
Conclusions
Fertility is the leading attribute of female life. It is strictly 
dependent on individual’s age. Nowadays, there is strong 
tendency to postpone entry to motherhood. Therefore, oocyte 
factors (decrease in oocyte quantity and quality) are the main 
causes responsible for decrease of fertility in women of late 
reproductive age. Anti-Müllerian (AMH) hormone seems to 
be the best endocrine marker for assessing the age-related 
decline of the ovarian pool in healthy women. AMH can be 
considered as an indicator of fertility in late reproductive 
age women and pregnancy outcome in assisted reproductive 
technology (ART) cycles. AMH can strongly predict poor 
response in the controlled ovarian stimulation.
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